Capricor Therapeutics (NASDAQ:CAPR) Trading Up 7.3% After Analyst Upgrade

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price traded up 7.3% during mid-day trading on Thursday after Cantor Fitzgerald raised their price target on the stock from $25.00 to $30.00. Cantor Fitzgerald currently has an overweight rating on the stock. Capricor Therapeutics traded as high as $18.25 and last traded at $18.15. 216,121 shares changed hands during trading, a decline of 81% from the average session volume of 1,141,077 shares. The stock had previously closed at $16.91.

A number of other analysts have also recently issued reports on CAPR. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Maxim Group boosted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.33.

Insider Activity at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The stock was bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics during the 1st quarter worth approximately $40,000. Main Street Financial Solutions LLC lifted its holdings in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the period. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics in the third quarter worth $133,000. Bank of New York Mellon Corp increased its holdings in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics during the 3rd quarter worth $161,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

The company has a fifty day simple moving average of $14.63 and a 200 day simple moving average of $8.29. The stock has a market capitalization of $824.19 million, a price-to-earnings ratio of -18.18 and a beta of 4.00.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.